

Supplementary Appendix

Supplementary Table 1: Detailed characteristics of included studies

S. No	Author/Year	Study Type	Study Location	Study Duration	LVAD Type	Subjects	Mean Age±SD	Male (%)	Mean BMI±SD	Mean LVEF ±SD	Cardiomyopathy types n (%)	NYHA Class n (%)	INTERMACS profile	Mean Pro-BNP (pg/ml)	Medications n (%)	Co-Morbidities	Mean Follow up
1	Raheja/2019	Retrospective	Henry Ford Hospital Detroit, USA	2006-2013	HeartMateII 114 (88%) HeartWare 15 (12%)	129	55±12	77%	NA	NA	NICM 82 (64%), ICM 47 (36%)	NA	NA	NA	NA	COPD 25 (19%)	676 days
2	Sajgalik /2018	Retrospective	Mayo Clinic, Rochester , USA	2007-2015	HeartMateII 33 (77%), HeartWare 11 (23%)	44	59±9	75%	28.7±4.7	21±13	NICM 23 (52%) ICM 17 (39%) HCM 4 (9%)	III+ 4 (10) IV 40 (90)	I 1 (2%), II 12 (27%), III 8 (18%), IV 19 (44%), V 3 (7%), VI 1 (2%)	5744±868	BB 41 (93) ACE-I/ARB 24 (54) Amiodarone 26 (59)	DM15 (34%), HTN 21 (47%) COPD 8 (18%), OSA 16 (36%) CKD 30 (68%), HLD 19 (43%), AF 25 (56%), Smoking 10 (22%)	237 days
3	Imamura/2016	Retrospective	University of Tokyo, Japan	2008-2015	EVAHEART 9 (41%) DuraHeart 8 (36%), Jarvik 2 (9%) HeartMateII 3 (14%)	22	42±13	73%	20.6 ± 2.4	NA	NICM 21 (95%) ICM 1 (5%)	NA	I 0%, II 14 (64%), III 8 (36%)	1037 ± 624	NA	NA	NA
4	Mohamedali/2015	Retrospective	Rush University , Chicago, USA	2007-2013	HeartMateII 14 (58%) HeartWare 10 (42%)	24	61±9	67%	30.2±5.7	19±7	NICM 10 (42%), ICM 14 (58%)	NA	NA	NA	NA	Smoker 10 (42%), HTN 16 (67%), CAD14 (58%), DM 11 (46%), COPD 7 (29%) CKD 15 (63%), CVA 4 (17%)	302 days

Abbreviations: NA: not available, USA, United States of America, NICM: Non-ischemic cardiomyopathy, COPD: chronic obstructive pulmonary disease, DM: diabetes mellitus, CKD: chronic kidney disease, CVA: cerebrovascular accident, BB: beta-blocker, ACEi: angiotensin converting enzymes inhibitors, ARB: angiotensin receptor blockers, HTN: hypertension